Tuberculosis drugs: New candidates and how to find more

Future Microbiology

Volumn 6, Issue 6, 2011, Pages 617-633

  Sala, Claudia ^a   Hartkoorn, Ruben C ^a  

^a EPFL   (Switzerland)

Author keywords

drug discovery; high throughput screening; lead; model; Mycobacterium; target; tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZD 5847; BEDAQUILINE; BETA LACTAM; BTZ 043; CLAVULANIC ACID; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LINEZOLID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PNU 100480; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESAZURIN; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

BACTERIAL VIABILITY; BACTERIUM; BIOCHEMISTRY; BIOPHYSICS; CELL ASSAY; CELL SCREENING; COMPUTER MODEL; DRUG DESIGN; DRUG DEVELOPMENT; DRUG SCREENING; DRUG WITHDRAWAL; HIGH THROUGHPUT SCREENING; HUMAN; NONHUMAN; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; WHOLE CELL;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MYCOBACTERIUM; TUBERCULOSIS;

MYCOBACTERIUM;

EID: 79959794071     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.11.46     Document Type: Review

References (128)

1. Dye C: Global epidemiology of tuberculosis. Lancet 367(9514), 938-940 (2006
2. Boshoff HI, Barry CE 3rd: Tuberculosis - metabolism and respiration in the absence of growth. Nat. Rev. Microbiol. 3(1), 70-80 (2005 (Pubitemid 40028470)
3. Chan J, Flynn J: The immunological aspects of latency in tuberculosis. Clin. Immunol. 110(1), 2-12 (2004 (Pubitemid 38177416)
4. Gomez JE, McKinney JD: M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis 84(1-2), 29-44 (2004 (Pubitemid 38082931)
5. Collins KR, Quinones-Mateu ME, Toossi Z, Arts EJ: Impact of tuberculosis on HIV-1 replication, diversity, and disease progression. AIDS Rev. 4(3), 165-176 (2002 (Pubitemid 35251994)
6. Dooley KE, Chaisson RE: Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect. Dis. 9(12), 737-746 (2009
7. Stevenson CR, Critchley JA, Forouhi NG et al.: Diabetes and the risk of tuberculosis: a neglected threat to public health? Chronic Illn. 3(3), 228-245 (2007 (Pubitemid 351927860)
8. Stevenson CR, Forouhi NG, Roglic G et al.: Diabetes and tuberculosis: the impact of the diabetes epidemic on tuberculosis incidence. BMC Public Health 7, 234 (2007
9. Shi R, Sugawara I: Development of new anti-tuberculosis drug candidates. Tohoku J. Exp. Med. 221(2), 97-106 (2010
10. Andries K, Verhasselt P, Guillemont J et al.: A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307(5707), 223-227 (2005 (Pubitemid 40116230)
11. Koul A, Dendouga N, Vergauwen K et al.: Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3(6), 323-324 (2007 (Pubitemid 46789271)
12. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI: Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother. 54(3), 1022-1028 (2010
13. Koul A, Vranckx L, Dendouga N et al.: Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J. Biol. Chem. 283(37), 25273-25280 (2008
14. Rao SP, Alonso S, Rand L, Dick T, Pethe K: The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 105(33), 11945-11950 (2008
15. Sala C, Dhar N, Hartkoorn RC et al.: Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 54(10), 4150-4158 (2010
16. Lenaerts AJ, Hoff D, Aly S et al.: Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by r207910. Antimicrob. Agents Chemother. 51(9), 3338-3345 (2007 (Pubitemid 350067549)
17. Shang S, Shanley CA, Caraway ML et al.: The activity of TMC 207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob. Agents Chemother. 55(1), 124-131 (2011
18. Gelber R, Andries K, Paredes RM, Andaya CE, Burgos J: The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently. Antimicrob. Agents Chemother. 53(9), 3989-3991 (2009
19. Diacon AH, Pym A, Grobusch M et al.: The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360(23), 2397-2405 (2009
20. Rustomjee R, Diacon AH, Allen J et al.: Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52(8), 2831-2835 (2008
21. Stover CK, Warrener P, VanDevanter DR et al.: A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405(6789), 962-966 (2000 (Pubitemid 30435054)
22. Manjunatha UH, Lahiri R, Randhawa B, Dowd CS, Krahenbuhl JL, Barry CE 3rd: Mycobacterium leprae is naturally resistant to PA-824. Antimicrob. Agents Chemother. 50(10), 3350-3354 (2006 (Pubitemid 44527509)
23. Barry CE 3rd, Boshoff HI, Dowd CS: Prospects for clinical introduction of nitroimidazole antibiotics for the treatment of tuberculosis. Curr. Pharm. Des. 10(26), 3239-3262 (2004 (Pubitemid 39276613)
24. Manjunatha UH, Boshoff H, Dowd CS et al.: Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103(2), 431-436 (2006 (Pubitemid 43122418)
25. Manjunatha U, Boshoff HI, Barry CE: The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun. Integr. Biol. 2(3), 215-218 (2009
26. Singh R, Manjunatha U, Boshoff HI et al.: PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 322(5906), 1392-1395 (2008 (Pubitemid 352775253)
27. Diacon AH, Dawson R, Hanekom M et al.: Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother. 54(8), 3402-3407 (2010
28. Ginsberg AM, Laurenzi MW, Rouse DJ, Whitney KD, Spigelman MK: Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrob. Agents Chemother. 53(9), 3720-3725 (2009
29. Matsumoto M, Hashizume H, Tomishige T et al.: OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 3(11), E466 (2006
30. Sasaki H, Haraguchi Y, Itotani M et al.: Synthesis and antituberculosis activity of a novel series of optically active 6-nitro-2,3- dihydroimidazo[2,1- b]oxazoles. J. Med. Chem. 49(26), 7854-7860 (2006 (Pubitemid 46033674)
31. Condos R, Hadgiangelis N, Leibert E, Jacquette G, Harkin T, Rom WN: Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. Chest 134(1), 187-192 (2008 (Pubitemid 352008783)
32. Barbachyn MR, Hutchinson DK, Brickner SJ et al.: Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J. Med. Chem. 39(3), 680-685 (1996 (Pubitemid 26069690)
33. Williams KN, Stover CK, Zhu T et al.: Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob. Agents Chemother. 53(4), 1314-1319 (2009
34. Shinabarger D: Mechanism of action of the oxazolidinone antibacterial agents. Expert Opin. Investig. Drugs 8(8), 1195-1202 (1999 (Pubitemid 29410576)
35. Ippolito JA, Kanyo ZF, Wang D et al.: Crystal structure of the oxazolidinone antibiotic linezolid bound to the 50S ribosomal subunit. J. Med. Chem. 51(12), 3353-3356 (2008 (Pubitemid 351874992)
36. Wallis RS, Jakubiec WM, Kumar V et al.: Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 202(5), 745-751 (2010
37. Ginsberg AM: Drugs in development for tuberculosis. Drugs 70(17), 2201-2214 (2010
38. Lalloo UG, Ambaram A: New antituberculous drugs in development. Curr. HIV/AIDS Rep. 7(3), 143-151 (2010
39. Protopopova M, Hanrahan C, Nikonenko B et al.: Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J. Antimicrob. Chemother. 56(5), 968-974 (2005 (Pubitemid 41631930)
40. Nikonenko BV, Protopopova M, Samala R, Einck L, Nacy CA: Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob. Agents Chemother. 51(4), 1563-1565 (2007 (Pubitemid 46586854)
41. Jia L, Tomaszewski JE, Hanrahan C et al.: Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol. 144(1), 80-87 (2005 (Pubitemid 40192564)
42. Meng Q, Luo H, Chen Y, Wang T, Yao Q: Synthesis of novel [1,2]-diamines with antituberculosis activity. Bioorg. Med. Chem. Lett. 19(18), 5372-5375 (2009
43. Onajole OK, Govender P, van Helden PD et al.: Synthesis and evaluation of SQ109 analogues as potential anti-tuberculosis candidates. Eur. J. Med. Chem. 45(5), 2075-2079 (2010
44. Makarov V, Manina G, Mikusova K et al.: Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324(5928), 801-804 (2009
45. Pasca MR, Degiacomi G, Ribeiro AL et al.: Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob. Agents Chemother. 54(4), 1616-1618 (2010
46. Christophe T, Jackson M, Jeon HK et al.: High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5(10), E1000645 (2009
47. Magnet S, Hartkoorn RC, Szekely R et al.: Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis 90(6), 354-360 (2010
48. Trefzer C, Rengifo-Gonzalez M, Hinner MJ et al.: Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-d-ribose 2′-epimerase DprE1 of Mycobacterium tuberculosis. J. Am. Chem. Soc. 132(39), 13663-13665 (2010
49. Ghuysen JM: Serine β-lactamases and penicillin-binding proteins. Annu. Rev. Microbiol. 45, 37-67 (1991
50. Kwon HH, Tomioka H, Saito H: Distribution and characterization of beta-lactamases of mycobacteria and related organisms. Tuber. Lung Dis. 76(2), 141-148 (1995
51. Chambers HF, Moreau D, Yajko D et al.: Can penicillins and other beta-lactam antibiotics be used to treat tuberculosis? Antimicrob. Agents Chemother. 39(12), 2620-2624 (1995
52. Gupta R, Lavollay M, Mainardi JL, Arthur M, Bishai WR, Lamichhane G: The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin. Nat. Med. 16(4), 466-469 (2010
53. Lavollay M, Arthur M, Fourgeaud M et al.: The peptidoglycan of stationary-phase Mycobacterium tuberculosis predominantly contains cross-links generated by l,d-transpeptidation. J. Bacteriol. 190(12), 4360-4366 (2008 (Pubitemid 351812884)
54. Hugonnet JE, Tremblay LW, Boshoff HI, Barry CE 3rd, Blanchard JS: Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis. Science 323(5918), 1215-1218 (2009
55. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65(1-2), 55-63 (1983 (Pubitemid 14203433)
56. Caviedes L, Delgado J, Gilman RH: Tetrazolium microplate assay as a rapid and inexpensive colorimetric method for determination of antibiotic susceptibility of Mycobacterium tuberculosis. J. Clin. Microbiol. 40(5), 1873-1874 (2002 (Pubitemid 34493180)
57. De Logu A, Uda P, Pellerano ML, Pusceddu MC, Saddi B, Schivo ML: Comparison of two rapid colorimetric methods for determining resistance of Mycobacterium tuberculosis to rifampin, isoniazid, and streptomycin in liquid medium. Eur. J. Clin. Microbiol. Infect. Dis. 20(1), 33-39 (2001 (Pubitemid 32200359)
58. Mshana RN, Tadesse G, Abate G, Miorner H: Use of 3-(4,5-dimethylthiazol- 2- yl)-2,5-diphenyl tetrazolium bromide for rapid detection of rifampin-resistant Mycobacterium tuberculosis. J. Clin. Microbiol. 36(5), 1214-1219 (1998 (Pubitemid 28208001)
59. Changsen C, Franzblau SG, Palittapongarnpim P: Improved green fluorescent protein reporter gene-based microplate screening for antituberculosis compounds by utilizing an acetamidase promoter. Antimicrob. Agents Chemother. 47(12), 3682-3687 (2003 (Pubitemid 37484971)
60. Cho SH, Warit S, Wan B, Hwang CH, Pauli GF, Franzblau SG: Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51(4), 1380-1385 (2007 (Pubitemid 46586820)
61. Collins LA, Torrero MN, Franzblau SG: Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42(2), 344-347 (1998 (Pubitemid 28114442)
62. Ananthan S, Faaleolea ER, Goldman RC et al.: High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. Tuberculosis 89(5), 334-353 (2009
63. Maddry JA, Ananthan S, Goldman RC et al.: Antituberculosis activity of the molecular libraries screening center network library. Tuberculosis 89(5), 354-363 (2009
64. Lougheed KE, Taylor DL, Osborne SA, Bryans JS, Buxton RS: New anti-tuberculosis agents amongst known drugs. Tuberculosis 89(5), 364-370 (2009
65. Wayne LG: Dormancy of Mycobacterium tuberculosis and latency of disease. Eur. J. Clin. Microbiol. Infect. Dis. 13(11), 908-914 (1994
66. Wayne LG, Hayes LG: An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64(6), 2062-2069 (1996 (Pubitemid 26165667)
67. Wayne LG, Sohaskey CD: Nonreplicating persistence of Mycobacterium tuberculosis. Annu. Rev. Microbiol. 55, 139-163 (2001 (Pubitemid 32978103)
68. Wayne LG, Sramek HA: Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38(9), 2054-2058 (1994 (Pubitemid 24278800)
69. Hu Y, Mangan JA, Dhillon J et al.: Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J. Bacteriol. 182(22), 6358-6365 (2000
70. Deb C, Lee CM, Dubey VS et al.: A novel in vitro multiple-stress dormancy model for Mycobacterium tuberculosis generates a lipid-loaded, drug-tolerant, dormant pathogen. PLoS ONE 4(6), E6077 (2009
71. Hussain S, Malik M, Shi L, Gennaro ML, Drlica K: In vitro model of mycobacterial growth arrest using nitric oxide with limited air. Antimicrob. Agents Chemother. 53(1), 157-161 (2009
72. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K: Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol. Microbiol. 43(3), 717-731 (2002 (Pubitemid 34597265)
73. van der Wel N, Hava D, Houben D et al.: M. tuberculosis and M. leprae translocate from the phagolysosome to the cytosol in myeloid cells. Cell 129(7), 1287-1298 (2007 (Pubitemid 46962098)
74. Hartkoorn RC, Chandler B, Owen A et al.: Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein. Tuberculosis 87(3), 248-255 (2007 (Pubitemid 46551848)
75. Pethe K, Sequeira PC, Agarwalla S et al.: A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy. Nat. Commun. 1(5), 1-8 (2010
76. Banerjee A, Dubnau E, Quemard A et al.: inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263(5144), 227-230 (1994 (Pubitemid 24067929)
77. Vilcheze C, Wang F, Arai M et al.: Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat. Med. 12(9), 1027-1029 (2006 (Pubitemid 44353383)
78. Belanger AE, Besra GS, Ford ME et al.: The embAB genes of Mycobacterium avium encode an arabinosyl transferase involved in cell wall arabinan biosynthesis that is the target for the antimycobacterial drug ethambutol. Proc. Natl Acad. Sci. USA 93(21), 11919-11924 (1996 (Pubitemid 26347224)
79. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, Barry CE 3rd: The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J. Biol. Chem. 279(38), 40174-40184 (2004 (Pubitemid 39258293)
80. Cole ST, Brosch R, Parkhill J et al.: Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393(6685), 537-544 (1998 (Pubitemid 28319235)
81. MacLean D, Jones JD, Studholme DJ: Application of 'next-generation' sequencing technologies to microbial genetics. Nat. Rev. Microbiol. 7(4), 287-296 (2009
82. Parish T, Stoker NG: Development and use of a conditional antisense mutagenesis system in mycobacteria. FEMS Microbiol. Lett. 154(1), 151-157 (1997 (Pubitemid 27376750)
83. Blokpoel MC, Murphy HN, O'Toole R et al.: Tetracycline-inducible gene regulation in mycobacteria. Nucleic Acids Res. 33(2), E22 (2005
84. Ehrt S, Guo XV, Hickey CM et al.: Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res. 33(2), E21 (2005
85. Berens C, Hillen W: Gene regulation by tetracyclines. Constraints of resistance regulation in bacteria shape TetR for application in eukaryotes. Eur. J. Biochem. 270(15), 3109-3121 (2003 (Pubitemid 36930176)
86. Gossen M, Bujard H: Anhydrotetracycline, a novel effector for tetracycline controlled gene expression systems in eukaryotic cells. Nucleic Acids Res. 21(18), 4411-4412 (1993 (Pubitemid 23279051)
87. Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S: Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc. Natl Acad. Sci. USA 107(21), 9819-9824 (2010
88. Guo XV, Monteleone M, Klotzsche M et al.: Silencing Mycobacterium smegmatis by using tetracycline repressors. J. Bacteriol. 189(13), 4614-4623 (2007 (Pubitemid 47025573)
89. Gandotra S, Schnappinger D, Monteleone M, Hillen W, Ehrt S: In vivo gene silencing identifies the Mycobacterium tuberculosis proteasome as essential for the bacteria to persist in mice. Nat. Med. 13(12), 1515-1520 (2007 (Pubitemid 350224249)
90. Forti F, Crosta A, Ghisotti D: Pristinamycin-inducible gene regulation in mycobacteria. J. Biotechnol. 140(3-4), 270-277 (2009
91. Salah-Bey K, Thompson CJ: Unusual regulatory mechanism for a Streptomyces multidrug resistance gene, ptr, involving three homologous protein-binding sites overlapping the promoter region. Mol. Microbiol. 17(6), 1109-1119 (1995
92. Boldrin F, Casonato S, Dainese E et al.: Development of a repressible mycobacterial promoter system based on two transcriptional repressors. Nucleic Acids Res. 38(12), E134 (2010
93. Kim JH, Wei JR, Wallach JB, Robbins RS, Rubin EJ, Schnappinger D: Protein inactivation in mycobacteria by controlled proteolysis and its application to deplete the beta subunit of RNA polymerase. Nucleic Acids Res. 39(6), 2210-2220 (2010
94. Keiler KC: Biology of trans-translation. Annu. Rev. Microbiol. 62, 133-151 (2008
95. Levchenko I, Seidel M, Sauer RT, Baker TA: A specificity-enhancing factor for the ClpXP degradation machine. Science 289(5488), 2354-2356 (2000
96. Wehrli W, Knusel F, Schmid K, Staehelin M: Interaction of rifamycin with bacterial RNA polymerase. Proc. Natl Acad. Sci. USA 61(2), 667-673 (1968
97. Wehrli W, Knusel F, Staehelin M: Action of rifamycin on RNA-polymerase from sensitive and resistant bacteria. Biochem. Biophys. Res. Commun. 32(2), 284-288 (1968
98. Munoz-Elias EJ, McKinney JD: Mycobacterium tuberculosis isocitrate lyases 1 and 2 are jointly required for in vivo growth and virulence. Nat. Med. 11(6), 638-644 (2005 (Pubitemid 40868304)
99. Stallings CL, Stephanou NC, Chu L, Hochschild A, Nickels BE, Glickman MS: CarD is an essential regulator of rRNA transcription required for Mycobacterium tuberculosis persistence. Cell 138(1), 146-159 (2009
100. Lin G, Li D, de Carvalho LP et al.: Inhibitors selective for mycobacterial versus human proteasomes. Nature 461(7264), 621-626 (2009
101. Sassetti CM, Boyd DH, Rubin EJ: Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol. 48(1), 77-84 (2003 (Pubitemid 36411469)
102. Sassetti CM, Rubin EJ: Genetic requirements for mycobacterial survival during infection. Proc. Natl Acad. Sci. USA 100(22), 12989-12994 (2003 (Pubitemid 37340013)
103. Cole ST, Eiglmeier K, Parkhill J et al.: Massive gene decay in the leprosy bacillus. Nature 409(6823), 1007-1011 (2001 (Pubitemid 32204045)
104. Cole ST: Comparative mycobacterial genomics as a tool for drug target and antigen discovery. Eur. Respir. J. Suppl. 36, S78-S86 (2002
105. Ioerger TR, Sacchettini JC: Structural genomics approach to drug discovery for Mycobacterium tuberculosis. Curr. Opin. Microbiol. 12(3), 318-325 (2009
106. He X, Alian A, Ortiz de Montellano PR: Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamides. Bioorg. Med. Chem. 15(21), 6649-6658 (2007 (Pubitemid 47385250)
107. Hegymegi-Barakonyi B, Szekely R, Varga Z et al.: Signalling inhibitors against Mycobacterium tuberculosis - early days of a new therapeutic concept in tuberculosis. Curr. Med. Chem. 15(26), 2760-2770 (2008
108. Szekely R, Waczek F, Szabadkai I et al.: A novel drug discovery concept for tuberculosis: inhibition of bacterial and host cell signalling. Immunol. Lett. 116(2), 225-231 (2008
109. Ciulli A, Abell C: Fragment-based approaches to enzyme inhibition. Curr. Opin. Biotechnol. 18(6), 489-496 (2007
110. Hung AW, Silvestre HL, Wen S, Ciulli A, Blundell TL, Abell C: Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angew. Chem. Int. Ed. Engl. 48(45), 8452-8456 (2009
111. Rawls KA, Lang PT, Takeuchi J et al.: Fragment-based discovery of selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatase PtpA. Bioorg. Med. Chem. Lett. 19(24), 6851-6854 (2009
112. Soellner MB, Rawls KA, Grundner C, Alber T, Ellman JA: Fragment-based substrate activity screening method for the identification of potent inhibitors of the Mycobacterium tuberculosis phosphatase PtpB. J. Am. Chem. Soc. 129(31), 9613-9615 (2007 (Pubitemid 47237472)
113. Scheich C, Puetter V, Schade M: Novel small molecule inhibitors of MDR Mycobacterium tuberculosis by NMR fragment screening of antigen 85C. J. Med. Chem. (2010
114. Kumar M, Verma S, Sharma S, Srinivasan A, Singh TP, Kaur P: Structure-based in silico design of a high-affinity dipeptide inhibitor for novel protein drug target Shikimate kinase of Mycobacterium tuberculosis. Chem. Biol. Drug Des. 76(3), 277-284 (2010
115. Kumar M, Vijayakrishnan R, Subba Rao G: In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis dihydrofolate reductase, a potential target for anti-TB drug discovery. Mol. Divers. 14(3), 595-604 (2010
116. Payne RJ, Peyrot F, Kerbarh O, Abell AD, Abell C: Rational design, synthesis, and evaluation of nanomolar type II dehydroquinase inhibitors. ChemMedChem 2(7), 1015-1029 (2007
117. Lin TW, Melgar MM, Kurth D et al.: Structure-based inhibitor design of AccD5, an essential acyl-CoA carboxylase carboxyltransferase domain of Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 103(9), 3072-3077 (2006 (Pubitemid 43346426)
118. Sullivan TJ, Truglio JJ, Boyne ME et al.: High affinity InhA inhibitors with activity against drug-resistant strains of Mycobacterium tuberculosis. ACS Chem. Biol. 1(1), 43-53 (2006
119. Kuo MR, Morbidoni HR, Alland D et al.: Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural data. J. Biol. Chem. 278(23), 20851-20859 (2003 (Pubitemid 36806391)
120. Gupta RK, Thakur TS, Desiraju GR, Tyagi JS: Structure-based design of DevR inhibitor active against nonreplicating Mycobacterium tuberculosis. J. Med. Chem. 52(20), 6324-6334 (2009
121. Barker JJ: Antibacterial drug discovery and structure-based design. Drug Discov. Today 11(9-10), 391-404 (2006
122. Kantardjieff K, Rupp B: Structural bioinformatic approaches to the discovery of new antimycobacterial drugs. Curr. Pharm. Des. 10(26), 3195-3211 (2004 (Pubitemid 39276609)
123. Weber W, Schoenmakers R, Keller B et al.: A synthetic mammalian gene circuit reveals antituberculosis compounds. Proc. Natl Acad. Sci. USA 105(29), 9994-9998 (2008
124. Willand N, Dirie B, Carette X et al.: Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat. Med. 15(5), 537-544 (2009
125. Engohang-Ndong J, Baillat D, Aumercier M et al.: EthR, a repressor of the TetR/CamR family implicated in ethionamide resistance in mycobacteria, octamerizes cooperatively on its operator. Mol. Microbiol. 51, 175-188 (2004 (Pubitemid 38031080)
126. Holdiness MR: Neurological manifestations and toxicities of the antituberculosis drugs. A review. Med. Toxicol. 2(1), 33-51 (1987 (Pubitemid 17001248)
127. Weinstein HJ, Hallett WY, Sarauw AS: The absorption and toxicity of ethionamide. Am. Rev. Respir. Dis. 86, 576-578 (1962
128. Collins L, Franzblau SG: Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 41(5), 1004-1009 (1997) (Pubitemid 27194176)